Real-World Utilization of a Proteomic Biomarker Panel for Assessing Multiple Sclerosis Disease Activity in an Academic Multiple Sclerosis Clinic with a Diverse Patient Population
Research Presented at ACTRIMS 2024 - February 29 - March 1
Comparison of Natalizumab, Ocrelizumab, and Diroximel Fumarate in RRMs Patients Stable on Therapy to Characterize Proteomic, Radiomic, and Clinical Trajectories: Study Design
Research Presented at ACTRIMS 2024 - February 29 - March 1
Performance Comparison of a Multi-Protein Multiple Sclerosis Disease Activity Test for Blood Serum Samples That Were Collected Before Versus After the MRI Scan
Research Presented at MSMilan 2023 - October 11-13
Real-World Utilization of a Proteomic Biomarker Panel for Assessing Multiple Sclerosis Disease Activity in an Academic Multiple Sclerosis Clinic with a Diverse Patient Population
Research Presented at ACTRIMS 2024 - February 29 - March 1
Comparison of Natalizumab, Ocrelizumab, and Diroximel Fumarate in RRMs Patients Stable on Therapy to Characterize Proteomic, Radiomic, and Clinical Trajectories: Study Design
Research Presented at ACTRIMS 2024 - February 29 - March 1
Performance Comparison of a Multi-Protein Multiple Sclerosis Disease Activity Test for Blood Serum Samples That Were Collected Before Versus After the MRI Scan
Research Presented at MSMilan 2023 - October 11-13